Investors

We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.

Shuang Yang, Scientist, China

Second quarter 2024 results

Second quarter 2024 results were reviewed by management during a conference call with the financial community. The presentation was followed by a Q&A session.

Thursday July 25, 2024
14:30 - 16:00 CET (8:30am – 10am EST)

Upcoming Events

18Sep

2024

UBS Annual Bus Tour

12:00 - 02:00 CEST

Broker Conference

19Sep

2024

BofA Securities Global Healthcare Conference 2024

08:00 - 13:00 BST (UK time)

Broker Conference

20Sep

2024

Investor Science Call from ECTRIMS

Friday, September 20, 2024 from 16:00 CEST / 10:00am EDT / 07:00 am PDT

16:00 CEST

Investor Presentation

Discover more

Press Releases

September 12, 2024
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
September 11, 2024
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
September 11, 2024
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
Dr. Lingaraju checks the health of Manikantan as his sister Geetha watches closely inside the Billigiri Ranganathaswamy Temple Tiger Reserve in Chamrajanagara district, Karnataka state, India
Dr. Lingaraju checks the health of Manikantan as his sister Geetha watches closely inside the Billigiri Ranganathaswamy Temple Tiger Reserve in Chamrajanagara district, Karnataka state, India

Environment, Social, Governance

As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.

2023 20-F

Presenting our 2023 FORM 20-F.

Subscribe to investor email alerts

Sign up to receive email alerts for various types of investor content

Contact Our Investor Relations Team

To join the Sanofi front desk,

Please contact the Global Headquarters in France :
+33 (0)1 53 77 40 00

To contact the Investor Relations team:

46 avenue de la Grande Armée
75017 Paris FRANCE
investor.relations (at) sanofi.com